FDA approves new Alzheimer's treatment regimen - PharmaTimes Patients and care partners may find once every four weeks maintenance dosing easier

#neurology #Neurodegeneration #biotech #ADpatients #dosingregimen #LEQEMBI #earlyAlzheimersdisease #Eisai #BiogenInc #phase2Study201 #ClarityADstudy #amyloidbetaplaques #amyloidbetaplaqueclearance #SupplementalBiologicsLicenseApplication #subcutaneousautoinjector
pharmatimes.com/news/fda-app...